Research Alliance III Raises $75 Million for Healthcare SPAC
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 49 minutes ago
0mins
Should l Buy RACC?
Source: renaissancecapital
- Funding Size: Research Alliance III successfully raised $75 million by offering 7.5 million shares at $10 each, indicating strong market interest and investment enthusiasm in the healthtech sector.
- Increased Share Offering: Originally planning to offer 5 million shares, the company increased its offering earlier this month, reflecting robust demand for its investment opportunities, potentially providing greater financial support for future acquisitions.
- Industry Focus: The SPAC targets healthcare-related industries, specifically drug development, commercialization, diagnostics, and healthcare technology services, aiming to drive innovation and growth through acquisitions, thereby strengthening RA Capital's influence in the sector.
- Transaction Arrangement: The company will trade on Nasdaq under the symbol RACC, with Leerink Partners acting as the sole bookrunner for the deal, ensuring a smooth fundraising process.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RACC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RACC
Wall Street analysts forecast RACC stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 10.000
Low
Averages
High
Current: 10.000
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
